Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00208-X/fulltext?dgcid=hubspot_update_feature_updatealerts_langas&utm_campaign=update-langas&utm_medium=email&_hsmi=279662021&_hsenc=p2ANqtz--x-iyp4hZmgFJ5x4PEhviWGWClg6t7SLI6pQX-VyWZF7DQdrMrZeAhy97RV5kp-HZM_fqEcp6tn2q0OCKUbA6f8Um-4w&utm_content=279615079&utm_source=hs_email